Logo

AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthma

Share this

AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthma

Shots:

  • The US FDA has approved the self-administration of Fasenra (benralizumab) in a pre-filled- single-use auto-injector- based on P-III GRECO and P-I AMES study
  • The P-III GRECO study involves assessing of Fasenra Pen with Fasenra (FD- 30mg- SC- q4w) in 120 patients with severe- uncontrolled asthma resulted in a 97% success rate of self-administration @12 & 16wks. The P-I AMES study compares the PK exposure following Fasenra (SC-30mg) in healthy people by using a pre-filled syringe or pre-filled auto-injector devices
  • Fasenra is the AstraZeneca’s first respiratory biologic (mAb) targeting IL-5 receptor alpha on eosinophils and attract NK cells to induce depletion of eosinophils via apoptosis and is approved as add-on maintenance treatment for SEA in the US- EU- Japan & other countries.

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image:AstraZeneca


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions